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Selenium (Se) is known to regulate carcinogenesis and immunity at nutritional 
and supranutritional levels. Because the immune system provides one of the main body 
defenses against cancer, we asked whether T cell immunity can modulate selenium 
chemoprevention. Homozygous NU/J nude mice were fed selenium-deficient, torula 
yeast basal diet alone or supplemented with 0.15 or 1 mg Se/kg for 8 months in 
Experiment 1 and for 11 weeks in Experiment 2. Mice were inoculated with PC-3 
prostate cancer cells followed by a 7-week tumor development. Peripheral T cells were 
analyzed at baseline, day 9, 19, 34 and 47 by flow cytometry. Tumor development in 
adult nude mice (Experiment 1) was suppressed whereas in young nude mice 
(Experiment 2) was promoted by feeding a high selenium diet. Dietary selenium 
deficiency does not affect tumor weight. After xenograft, dietary selenium status does not 
affect levels of CD4 and CD8 T cells in adult nude mice in Experiment 1, while high 
selenium resulted in significant decrease in CD4 T cells in young nude mice in 
Experiment 2.  Taken together, there is an opposing role of excessive selenium on tumor 
xenograft development in adult and young nude mice carrying differential T cell profiles. 
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CHAPTER I: INTRODUCTION 
Selenium 
Essential trace element 
Selenium as a chemical element was first discovered in 1818 by the Swedish 
chemist Jöns Jacob Berzelius (Weeks 1932). The first evidence of the importance of 
selenium in normal metabolic functions came in 1957 when selenium, even in very small 
amounts, was found to be the element that prevented necrotic liver degeneration in 
vitamin E-deficient rats fed torula yeast as protein source (Schwarz and Foltz 1957). The 
most effective compound of the element was found to be in the form of inorganic salt, 
sodium selenite. From these results, Schwarz and Foltz suggested that selenium is a  
essential trace element that may play a role in the oxidation reduction reactions. In fact, 
in 1973 glutathione peroxidase was the first selenium-containing enzyme to show 
antioxidant activity (Rotruck, Pope et al. 1973). By then, selenium has been recognized 
as an essential micronutrient of fundamental importance to human health (Driscoll and 
Copeland 2003). It is essential because its deficiency results in suboptimal biological 
function that is preventable and reversible if the element is added back to the diet. It is a 
micronutrient because only very small amounts are found in the body and the tissues and 
less than 100 mg per day is needed to sustain proper body and metabolic function 
(Gropper 2009). And it is important to human health because selenium functions in 
selenoenzymes that have antioxidant properties. 
Besides its role involving antioxidant defense systems, it has also been shown to 
play important role in immune function, thyroid hormone metabolism, anti-
carcinogenesis, anti-inflammatory and anti-viral activity (Brown 2001).  
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Chemical form, bioavailability and intake 
Selenium is available from food in organic form primarily as selenocysteine 
(SeC) and selenomethionine (SeM) or inorganic form as selenite (H2S O3), hydrogen 
selenide (H2Se) or selenate (H2SeO4) (Gropper 2009). In the United States, the 
recommended dietary allowance (RDA) for selenium is 55 µg/day for men and women 
and the tolerable upper intake limit (UL) has been set at 400 µg/day. The daily intake and 
recommended values vary with geographical location of selenium-containing food 
consumption as selenium content in the food is dependent on the amount of selenium in 
the soil (Levander 1987). Data from selenium intakes for most regions in the United 
States show sufficient amount of selenium, however, some countries, particularly in 
Europe and some parts of China and New Zeeland, have selenium intakes bellow the 
recommended values. As a result, selenium deficiency or suboptimal intake can occur 
among the populations. On the other hand, very high selenium intakes as directly related 
to the amount of selenium in the plants which absorb it from the soil, have been observed 
in countries such as Venezuela, parts of China, Northern US and Canada (Rayman 2004). 
 Too much selenium consumption can be toxic and leads to selenosis (Rayman 
2008). Forty µg of selenium per day is considered the minimal requirement to prevent 
adverse effects on human health as this is the amount to allow for full expression of mst
selenoproteins except selenoprotein P (Xia, Hill et al. 2005), whereas 200-400 µg is 
considered a supranutritional dose, a higher than nutritional dose but bellow toxic, which 
is above 800 µg per day. A study of selenium-deplete subjects showed that 66 µg 
selenium / day was not sufficient to reach optimal levels of selenoprotein P (Xia, Hill et 
al. 2005). On the other hand, selenium-replete subjects did not show increase in plasma 
selenoprotein P concentrations after supplementation with 200, 400, or 600 µg selenium / 
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day because the protein was already fully expressed (Burk, Norsworthy et al. 2006). So 
the required amount of selenium necessary to optimize selenoprotein P in selenium –
deficient subjects (plasma selenium <110 ng/ml) was addressed in a study by Hurt et al. 
The results showed that 50 µg selenium /day was sufficient to increase selenoprotei  P 
concentrations to a steady state after 10 weeks of supplementation. Additional sele ium 
(100 or 200 µg/day) did not further increase plasma selenoprotein P concentrations 
(Hurst, Armah et al. 2010). 
Saturation of selenoproteins occurs at the nutritional level as was shown in a 
study carried out in a selenium-deficient part of China, where Keshan disease was 
endemic. 120 subjects with an average intake of 10 µg selenium per day were given a 
supplement of either SeM or selenite. Maximum GPx activity was achieved by 
administering just 37 µg/day SeM or 66 µg/day selenite. Therefore, SeM has been shown 
to be twice as effective in maximizing GPx activity as selenite (Xia, Hill et al. 2005).  
Daily selenium requirement for optimal health is dependent on many factors such 
as the chemical species ingested, selenium status of the individual (deplete vs. replete), 
mechanism of action (antioxidant, anti-carcinogenic, antiviral), health condition 
(immune, cognitive, reproductive, viral, malignant), and even genomic differences 
between individuals or populations (Rayman 2008). The bioavailability of selenium is 
dependent on the form of selenium species ingested. Brazil nuts are the richest natural 
source of selenium ranging from 10 to 42 µg per nut with the most prevalent form being 
SeM (Thomson, Chisholm et al. 2008).  In dietary supplements, selenium is usually 
found as SeM, selenite or selenate.  
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The effect of supplementation on selenoprotein activity is dependent on the 
selenium status of the individual. In a study by Thomas et al, the effect of selenium-rich 
food and selenium supplement at the nutritional dose on selenium status was investigated 
in a randomized placebo-controlled trial of selenium-deplete adult males and females. 
Selenium status was determined by plasma selenium concentration and GPx activity at 
baseline and every 4 weeks for 12 weeks (Thomson, Chisholm et al. 2008). 
Another randomized placebo-controlled intervention of selenium-replete adult 
males and females assessed the effect of three different forms of high doses of sel nium 
supplements on selenium status. Three plasma selenium biomarkers and urinary sele ium 
excretion were measured at baseline and every 4 weeks for 16 weeks. The studies showed 
that selenium-depleted individuals show increase in selenoprotein activity whereas 
selenium-repleted individuals do not (Burk, Norsworthy et al. 2006; Thomson, Chisholm 
et al. 2008). The latter study concluded that SeM is the most bioavailable form of 
selenium species in food and should be the chemical form in supplements to increase 
absorption and retention of selenium in the body (Burk, Norsworthy et al. 2006).  
Though bioavailability of SeM seems to be higher than that of other selenium 
compounds, the metabolism is quite different depending on the chemical species, for 
instance, and as a result can have very different effects on the body as was shown in a 
study by Whanger et al (Whanger, Xia et al. 1993) conducted on selenium-depleted 
Chinese men supplemented with SeM or selenate. They showed that more selenium was 
associated with the GPx in plasma and red blood cells and extracted from the nails and 
hair in the group supplemented with selenate than SeM. SeM, however, was associated 
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with higher deposition in albumin protein. So it is important to include different selenium 
species when conducting studies as each can have varying effects.  
The different chemical forms of selenium that have been used in previous clinical, 
mouse, and cell studies include selenium-enriched yeast which contains a mix of organic 
forms of selenium, predominantly SeM, as well as elemental selenium (Duffield-Lillico, 
Reid et al. 2002), L-selenomethionine (Lippman, Goodman et al. 2005; Li, Lee et al. 
2008), seleno-L-methionine (Fischer, Mihelc et al. 2007) sodium selenate, Se 
methylselenocysteine, sodium selenite, and methyl seleninic acid (Li, Lee et al. 2008) 
among others.  
Selenium metabolism 
Selenium enters the food chain via plants that absorb it in the inorganic form from 
the soil (Papp, Lu et al. 2007) . Human enteric absorption of selenium differs for different 
chemical compounds but in general, it occurs in the lower intestine where they are 
metabolized to more reduced states. For example, selenate is reduced to selnite (Combs 
and Combs 1984). SeM has been found to be absorbed and stored the most efficiently 
(75%) whereas SeC and selenite as low as 45%. SeM actively competes for transpor  
with methionine in cecum and colon as primary sites of absorption using transmucosal 
uptake via concentration gradient whereas SeC does not (Combs and Combs 1984).  
It is interetesting to note that in both the rat and human balance studies the 
excretion is closely related to the dietary intake of selenium but below a certain threshold, 
the body seems to conserve selenium by limiting urinary excretion when selenium supply 
is sparse (Levander 1986). 
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The uptake of selenium can be increased by presence of vitamin A, E and C when 
dietary intake is higher than amounts normally required for these vitamins (Combs and 
Combs 1984). Transportation of selenium occurs primarily through association with 
plasma proteins. Since the organic forms of selenium are reduced to selenite by post 
absorptive catabolism, the metabolism of selenium is closely linked to selenite. Selenite 
is reduced to a readily transportable H2Se through a series of reactions involving thiols 
and NADPH molecules and catalyzed by glutathione reductase. Hydrogen selenide can 
further be methylated for secretion, oxidized to elemental selenium, or used as the 
precursor for selenoprotein synthesis. 
Since H2Se is the most toxic intermediary metabolite, the methylation process 
serves as detoxification mechanism. Dimethyl selenide is volatile and excret d in the 
lungs under high levels of selenium intake, whereas trimethyl selenonium cation is highly 
soluble and excreted in the urine to maintain selenium homeostasis (Combs and Combs 
1984). SeM is metabolized in the same pathway as methionine contributing to the 
methionine pool, and is interchangeable in non-specific protein synthesis (Sunde, Gutzke 
et al. 1981; Burk, Hill et al. 2001). When SeM is consumed in the form of food protein or 
supplements, it can be directly metabolized into SeC (Zeng 2009). Selenocysteine, whe  
consumed from the diet or as a product of SeM metabolism, is cleaved into H2Se. In turn, 
H2Se can enter another metabolic pathway that results in selenoprotein synthesis (Finley 
2006). Figure 1 bellow summarizes the metabolic pathways involved in selenium 
metabolism. 
 
Figure 1. Biochemical pathways of s
Selenoproteins 
Selenium is found in the body mainly bound to protein. Selenium is incorporated 
into proteins as elenocysteine 
Selenoproteins are a special
(Burk 1991). Selenocysteine is found in the catalytic site of the selenoenzymes 
et al. 2007). Selenocysteine has long been accepted by the research community as the 21
genetically encoded amino acid 
requires a unique Sec-charged tRNA containing UCA anticodon. UGA is normally  stop 
codon but in selenoprotein synthesis, UGA codes for SeC 
Copeland 2003). The fact that UGA is not read as the stop codon on the selenoprotein 
mRNA is due to a special SE
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elenium metabolism. Modified from 
(SeC) or selenomethionine (Papp, Lu et al. 2007)
 class of proteins containing specifically SeC
(Papp, Lu et al. 2007) The biosynthesis of selenoproteins 
(Burk 1991; Driscoll and 









the 3’untraslated region (3’UTR) of the mRNA. Interestingly, SeC is synthesized on its 
tRNA. SeC does not occur as free amino acid. Rather, it is inserted co-translationally into 
polypeptides. SeC specific tRNASec is first charged with serine by seryl tRNA synthetase 
that converts the seryl residue to selenocysteine using  monoselenophosphate as the 
selenium donor. Monoselenophosphate is synthesized from selenide (Driscoll and 
Copeland 2003; Allmang and Krol 2006). The physiological functions of selenium are 
exerted mainly through selenoproteins.  
As identified by genome-wide search of SECIS, humans contain 25 
selenoproteins (Kryukov, Castellano et al. 2003), Glutathione peroxidases-1 (GPx-1) was 
the first identified (Rotruck, Pope et al. 1973) and the most studied (Brown 2001) 
selenoprotein. The human selenoproteome consists of 17 selenoprotein families including 
glutathione peroxidases, thioredoxin reductases (TRs), iodothyronine deiodinases, and 
selenophosphate synthetases (Papp, Lu et al. 2007). GPx enzymes are involved in cellular 
antioxidant activity in the reduction of hydrogen peroxides and lipid peroxides, highly 
toxic molecules to the cell but by-products of normal metabolism. GPx is often used as a 
marker of selenium status, however, selenoprotein P is considered to be more 
representative as it contains almost 60% of the plasma selenium (Gropper 2009). In fact, 
together, the GPx3 and selenoprotein P contain over 90% of the total selenium in the 
plasma (Brown 2001).Therefore, they more or less represent overall selenium stat s in 
the body. Studies have also shown that the level of GPx decreases faster than that of 
selenoprotein P and other selenoproteins exhibiting hierarchy of synthesis (Dri coll and 
Copeland 2003). Saturation of selenoproteins occurs at below the supranutritional levels, 
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suggesting that anticarcinogenic properties come mainly from selenium metabolites 
rather than from selenoproteins (Combs and Gray 1998). 
Selenium and human health 
Though selenium deficiency is rare, it can occur in regions with selenium-poor 
soil (Combs and Gray 1998). Diseases associated with selenium deficiency ar marked 
by increased oxidative stress, and changes in redox signaling (Papp, Lu et al. 2007).  
Perhaps the best known selenium deficiency-induced disease is Keshan disease, a 
cardiomyopathy, once endemic in northern-east part of China (Rayman 2008). Keshan 
disease can be fatal resulting in heart failure and pulmonary edema. The symptoms can 
be reversed most of the time and the disease cured by selenium supplementation. The 
time from selenium deficiency and start of supplementation is critical as the recovery 
depends on the extent of myocardial necrosis. Supplement of 150 µg/day is 
recommended for patients with  heart failure associated with low plasma selenium vels 
(Saliba, El Fakih et al.).  
Kashin-Beck disease is another selenium deficiency-related disorder. The 
underlying factor for the joint and cartilage osteoarthropathy seems to be increased 
oxidative stress due to combined selenium and iodine deficiency that can lead to poor 
immune response and viral susceptibility (Rayman 2008).  
As is the case with any other chemicals, too much selenium can have adverse 
health effects as well. Selenosis, which is chronic selenium toxicity, occurs umulatively 
and happens if too much selenium is consumed either in the diet, such as in seleniferous 
areas, or as supplement. Toxicity of selenium is directly related to the solubility of the 
compound ingested. The more soluble, the more toxic the compound is. Symptoms of 
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selenium poisoning include, hair loss, garlic breath (from the excretion of the volatile 
metabolites), brittle nails, diarrhea, vomiting, skin lesions, restlessness, tachycardia, 
fatigue, convulsions and death as observed in humans and animal studies (Yang and Zhou 
1994; Rayman 2008). The amount of intake associated with selenium toxicity has been 
reported to be above 900 µg/day. 
Though not as obvious and manifested with severe symptoms, selenium 
inadequacy which is expected to be quite prevalent in the United States due to mal- or 
poor nutrition can have serious deleterious effects on the human health. Suboptimal 
selenium intake can contribute to viral infections, male infertility, depressed immunity, 
adverse mood states, and higher risk of cancer incidence (Brown 2001; Rayman 2008). 
Cancer prevention 
Epidemiological studies 
Numerous studies have contributed to the evidence that selenium has anti-
carcinogenic properties. The cancer preventive properties of selenium were first proposed 
by Shamberger and Frost 40 years ago based on geographical data in a number of studis 
that indicated an inverse relationship between the incidence of  mortality from cancer and 
the nutritional status of selenium in the population, as the amount of selenium in diet is 
closely related to the selenium content  in the soil in that particular region or country 
(Shamberg.Rj and Frost 1969). The epidemiological study by Clark found negative 
correlation between cancer rates and the amount of Se in the forage crop and concluded 
that counties with high selenium had lower rates of cancer, especially that of colon, lung, 
esophagus and bladder (Clark 1985). Other studies support these results. Based on a 
prospective study that assessed the effect of selenium status analyzed from toenail 
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clippings on prostate cancer incidence, the results showed that higher levels of s lenium 
intake were associated with lower risk of advanced prostate cancer (Yoshizawa, Willett et 
al. 1998). Recently, Vogt et al looked at serum selenium concentrations and the incidence 
of prostate cancer among American black and white men. The results again showed an 
inverse relationship between selenium status and cancer incidence (Vogt, Ziegler et al. 
2003). 
Clinical studies 
Clinical trials have also shown correlation between selenium supplements and 
reduced risk of certain types of cancers, in particular prostate cancer (Duffield-Lillico, 
Reid et al. 2002). The results of a 13 year long multicenter, double-blind, randomized, 
placebo-controlled cancer prevention trial (NPC) in which 1312 men (75%) and women 
(25%) were supplemented with a daily dose of 200 µg of selenium in the form of 
brewer’s enriched yeast, which contain 80% selenium as selenomethionine and theother 
20% are other selenium compounds, have the strongest evidence in support of the 
hypothesis that supplemental selenium in excess of the nutritional amount, may reduce 
the incidence of and mortality from carcinomas. The study was initially design d to 
assess the effect of long-term selenium supplementation on recurrent non-melano a skin 
cancer. There were no significant effects of the treatment on the skin cancer, howver, 
secondary results showed that selenium treatment was associated with decrease in total 
cancer incidence (RR=63) and carcinomas of the prostate (RR=51), colon (RR =46) but 
no effect on colon (RR=70). It should also be noted that not all the subjects benefited 
from the selenium treatment, in fact, the largest protective effect of selenium was most 
noticeable in men who started the trial with lowest prostate specific antigen (PSA, < 4 
12 
 
ng/ml) and lowest tertile of plasma selenium status and these resulted in a 65% decrease 
of prostate cancer incidence suggesting an early stage protection (Duffield-Lill co, Reid 
et al. 2002).  
Another even larger randomized, placebo-controlled double-blind prostate cancer
prevention clinical trial (SELECT) involved participation of 35,535 men. This trial was a 
selenium (200 µg/day from L-selenomethionine) and/or vitamin E (400 IU/day of all-rac-
α-tocopheryl acetate) or placebo supplementation for a minimum of 7 years, maximum of 
12 years (2011-2014) (Lippman, Goodman et al. 2005). Preliminary data showed that 
after a follow up of about 5.5 years the results indicated non-significant effect of 
selenium in form of L-selenomethionine or Vitamin E or the combination of both 
supplements on prostate cancer prevention as compared to placebo (Lippman, Klein et al. 
2009). This seemingly contradictory result of SELECT to NPC underlines the importance 
of the selection of selenium compound and the selenium status of the individual. It has 
been noted from the results of NPC that individuals with below optimal levels of 
selenium benefited the most from selenium supplementation. Men in SELECT had 
mostly selenium levels that were not low or suboptimal and as such it is possible that 
additional selenium was not beneficial in preventing prostate cancer. 
In vivo studies 
Since human clinical studies require much longer time, and for ethical reasons are 
not always possible to implement, numerous animal studies have shown selenium 
efficacy against carcinogenesis in many tumor models. Li et al in 2008 tested four 
selenium compounds, specifically methyl seleninic acid (MSeA), MSeC, SeMet and 
sodium selenite (Na2SeO3) in xenograft of two human prostate cancer cell lines (DU145 
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and PC-3) using athymic nude mice as the animal model. The results showed oral dose-
dependent response with MSeA exhibiting the highest inhibitory efficacy against human 
prostate cancer. The doses of selenium were 1 mg/kg body weight (b.w.) and 3 mg/kg 
b.w. and only sodium selenite showed evidence of genotoxicity at the 3 mg/kg dose. The 
efficacy of the compounds was lower against the PC-3 xenograft compared to the DU145 
xenograft. PC-3 cells are a later stage of prostate cancer cell line and are more aggressive 
and metastatic compared with the DU145 cell line. PC-3 cells are also p53-deficient and 
androgen-independent whereas DU145 cells are p53-proficient and androgen-dependent 
accounting for alternate signaling pathways. These factors possibly play role in the 
tumorigenesis and angiogenesis during cancer development and account for the different 
responses to selenium treatment in these two cancer cell lines.  
Erdman et al explored the effect of selenium, vitamin E and lycopene on growth 
of prostate tumors in male rats. The experimental diets were fed 4-6 weeks prior to tumor 
injections and contained either selenium as methylselenocysteine (1 mg/kg diet), 
lycopene (250 mg/kg diet), vitamin E as γ-tocopharol (200 mg/kg diet) or combinations 
of these. Only MSeC significantly reduced the tumor area, tumor weight and tumor 
weight/body weight ratio. However, the mechanism of action remains unknown 
(Lindshield, Ford et al. 2010).   
Bioavailability of selenium compounds may not play as important role in cancer 
prevention as it does in enhancement of antioxidant activity of selenoproteins. Finley and 
Davis conducted an experiment testing the anti-carcinogenic efficacy of high selenium-
broccoli in rats with chemically induced colon cancer. The rats were depleted for six
weeks and then repleted for 60 days and samples analyzed at intervals. The results 
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showed that Se-methyl selenocysteine (SeMSeC), the chemical form found in the high 
selenium-broccoli, has low bioavailability (no significant accumulation in tissues nor 
enhanced GPx activity) compared to SeM, selenite and selenate but had the highest 
reduction in cancer incidence.  The bioavailability of high selenium-broccoli was 
determined by analyzing the repletion of selenium in tissues and GPx acitivity (F nley 
and Davis 2001). 
Mechanisms of anticarcinogenic activity 
In vitro models have been used extensively to elucidate possible mechanisms by 
which selenium exerts its anticarcinogenic effects.  Hypotheses on pathways of action are 
still emerging and more research is needed in this area. It seems that anticarcinogenic 
activity can come from both the antioxidant role of selenoenzymes as well as prooxidant 
role of selenium metabolites of low molecular weight (Combs and Gray 1998; Drake 
2006) .  
In order to better understand these ideas, it is helpful to be familiar with the 
process of carcinogenesis and DNA damage. Carcinogenesis can be broadly classified in 
three-stages: initiation, promotion and progression. Initiation is the first stage of 
carcinogenesis and seems to occur quite rapidly. It is also an irreversible step. It i  the 
initial insult by a carcinogen that if not eliminated by detoxification ca le d to formation 
of reactive molecules or DNA adducts creating a damaged or pre-initiated cell. Unless the 
damage is repaired by the cell’s DNA damage repair machinery, the cell will divide and 
become an “initiated cell”. The second stage is the promotion, which can take several
years but is reversible and depends on the status of immune response, altered gene 
expression and enhanced cell division, which will affect the speed and degree of 
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accumulation of benign tumor cells also called pre-neoplastic cells. The third and last 
stage of carcinogenesis is progression, which can take up to ten years or longer but 
eventually leads to neoplastic cells, invasive growth and metastasis, which is often 
incurable. Progression is affected by additional mutations and expression of oncogenes r 
silencing of tumor supperessor genes (Surh 2003). 
 Selenium plays a role in the maintenance of genome stability but the pathways of 
mechanism are still to be elucidated. Previous studies have shown that selenium, at the 
supranutritional levels, can induce oxidative stress in vitro. Oxidative stress in turn 
activates DNA damage response (DDR) and the cascading signaling pathways t at lead 
to cell cycle arrest to allow time for repair and if irreparable lead to cellular senescence or 
apoptosis. Both cellular senescence and apoptosis are considered early barrie s of 
tumorigenesis (Bartkova, Rezaei et al. 2006). Therefore it is logical to hypothesize that 
selenoproteins such as GPx and/or TRs with antioxidant and redox regulation activity
could protect against oxidative damage caused by reactive oxygen species (ROS), such as 
singlet oxygen, hydrogen peroxide, and hydroxyl radical, and prevent the initiation st ge 
of carcinogenesis. In this case, selenium deficiency could increase cancer risk due to 
ROS accumulation.  
Since selenium doses above those sufficient for maximum selenoprotein activity 
have resulted in anticarcinogenic effect, selenium metabolites, other than selenoproteins, 
may also be responsible. Studies have shown that both organic and inorganic forms of 
selenium can have antitumorigenic activity (Combs and Gray 1998). The inorganic 
selenite is known to induce apoptosis in various cell models. Other studies pinpointed to 
methyl selenol acting as the main anticarcinogenic metabolite through activation of 
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caspase proteinases, a key family of proteins in the apoptotic pathway (Ganther 1999). 
The cancer protective property of MSeC was mentioned earlier (Finley a d Davis 2001). 
So it is likely that different selenium metabolites can act through different m chanisms 
during different stages of carcinogenesis.   
An emerging of selenium is radioprotection of normal tissue. In a randomized 
trial, women with post-operative endometrial cancer undergoing radiotherapy (RT) were 
given high dose of sodium selenite (500 or 300 µg/day). Not only did selenium 
supplementation prevent selenium deficiency, common side effect of RT, but it also 
reduced incidence of RT-induced diarrhea and improved overall 5-year survival rate 
(Micke, Schomburg et al. 2009; Muecke, Buentzel et al. 2009).  
Selenium and the immune system 
Selenium has been shown to play a functional role in the immune system. Early 
studies with mice demonstrated enhanced primary immune response with above 
nutritionally adequate dose of selenium (0.1 µg/g) (Levander 1986). On the other hand, 
supplementation of selenium-deficient Finnish men had no effect on the leukocyte 
migration inhibitory factor production by lymphocytes, even though plasma selenium 
concentrations increased more than 2-fold from 74 to 169 ng/ml (Levander 1986). More 
recently, immunologic responses attributed to selenium comes mainly from 
selenoproteins with antioxidant activity but the mechanistic pathways are not fully 
understood (Arthur, McKenzie et al. 2003). Selenium functions in the immune system as 
peroxide-reducing agents, enzymes in the hydroperoxide metabolism, and in the 
modulation of the respiratory burst among others (Spallholz, Boylan et al. 1990). Four 
selenoproteins (GPx1, GPx4, TR2, 15 kDa selenoprotein) have been isolated from T cells 
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with functions in the cell yet to be identified. Patients infected with HIV have been
shown to have low levels of selenium (Gladyshev, Stadtman et al. 1999), suggesting a 
role of selenium in viral infection. Experimental evidence suggests that selenium 
deficiency leads to less responsive immune system, selenium adequate diet boosts 
immune response, and selenium toxicity causes immunosuppression (Spallholz, Boylan 
et al. 1990). As mentioned above, selenium deficiency weakens the immune system and 
makes it more susceptible to viral infections such as the case with Keshan disease. 
Selenium affects immunity through antioxidant and redox mechanism 
The mechanisms by which selenium affects the immune system are  not clear 
(Shrimali, Irons et al. 2008). However, several studies point to a mechanism involving 
antioxidant activity of selenium in T cells. Recently, one such study proposed a 
mechanism of action that involves selenoproteins and their antioxidant activity in ROS 
modulation and T cells of the immune system. This model has been proposed based on 
the results from a study where mice were generated lacking selenoprotein expression in T 
cells. Activation and proliferation of T cells by T cell receptor signaling was greatly 
reduced by the absence of selenoprotein expression. It was also discovered that the 
mature T cells were functionally defective due to selenoprotein deficiency. ROS 
production was increased in the T cells isolated from the mice lacking selenoprotein 
expression and this was reversed by the addition of an antioxidant, N- cetyl cysteine 
(NAC), greatly supporting the antioxidant effect of these selenoproteins (Shrimali, Irons 
et al. 2008). Similar study was carried out by the same group on macrophages devoid of 
selenoproteins (Carlson, Yoo et al. 2009), which showed that selenoproteins were 
necessary for the antioxidant effect. 
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A very recent study by Hoffmann et al showed that dietary selenium ranging from 
0.08 to 1.0 mg/kg effects CD4+ T cell activation and differentiation through modulation 
of free thiols in a response induced by peptide/adjuvant using mouse model. High 
selenium diet (addition of 1.0 mg/kg sodium selenite to casein-based diet) increased 
proliferation and differentiation of CD4+ T cells while low selenium diet (0.08 mg/kg) 
reduced the activity of these T helper cells. There was also a shift toward the Th1 effector 
cell phenotype in the high selenium diet which can explain its role in an antiviral and 
antitumor robust immune response. They reported increased T cell receptor signaling in 
response to high dietary selenium that involves free thiol concentrations in CD4+ T cells. 
In conclusion, this study showed the importance of understanding the effect of selenium 
supplementation on Th1 immunity in association with declining immunity during aging 
and immune suppression during cancer.  (Hoffmann, Hashimoto et al.).  
Because there is a very close association between cancer and the immune system, 
the status of immune system plays an important role in combating cancer. In a study by 
Roy and Kiremidjian-Schumacher, 33 patients with head and neck squamous cell 
carcinomas were given 200 µg/day of sodium selenite or placebo starting on the day of 
surgery and radiotherapy for 8 weeks. The lymphocyte response to antigens was 
significantly increased in subjects with selenium supplementation. The enhancement of 
lymphocyte response has been linked to increased production of α, β and γ subunits of 





Adaptive immune system 
 
B cells and T cells are lymphocytes involved in adaptive immunity. B cells play 
important roles in the humoral immunity. T cells play major roles in cell-mediat d 
immunity. Even though, both B and T cells are produced in the bone marrow by the 
hematopoietic stem cells. The main difference between B cells and T cells is that B cells 
differentiate and mature in the bone marrow, whereas T cells travel to and mature in the 
thymus. There are more than 350 subsets of leukocytes, each of which is assigned a 
cluster differentiation (CD) number indicating a cell phenotype-determining antigen 
(Chaplin 2010).  
All mature leukocytes express specific cell surface antigens. Lymphocyte subsets 
(B cells, T cells, Natural Killer (NK) cells and NK-T cells) can be further discriminated 
by surface phenotype. T cells express T cell receptors (TCR). The majority of T cells 
expresses αβ TCR; those further differentiate into subsets, such as CD8+ T cells, are 
primarily involved in killing microbe-infected cells and tumor cells through their 
cytotoxic activity. In contrast, CD4+ T cells mainly mediate humoral and immune 
responses. CD8+ T cells also contain regulatory cells (suppressor cells) that can down-
regulate immune response (Chaplin 2010). Figure 2 depicts T cell differentiation and 
maturation designating the functionally distinct subpopulations and subsets. 
 
Figure 2. Maturation and differentiation o
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 Some circulatory CD4+ T cells, known as Treg cells, p ay important roles 
in suppressing the immune response. These Treg cells ar  further divided into two 
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Nude mice have been used extensively in xenograft tumor models and are the 
animal model used in the present study (Watrach, Milner et al. 1984; Lin, Boylan et al. 
1991; Li, Lee et al. 2008; Yang, Huang et al. 2009; Bai, Mao et al. 2010). The nude mice 
are immunosuppressed by virtue of lacking functional T lymphocytes and as such are 
well suited for tumor xenograft studies as they do not readily reject human cancer ells. 
The initial studies with nude mice were conducted using skin grafts from different 
animals and have been shown to be maintained indefinitely for the life of the animal
(Manning, Reed et al. 1973; Reed and Manning 1973). The purpose of the present study 
is to determine the effect of dietary selenium on tumor growth and extrathymic T cell 
maturation in adult nude mice inoculated with human prostate cancer (PC-3) cells. Th  
effect of aging on extrathymic T cell maturation in nude mice has been observed 
previously (Kennedy, Pierce et al. 1992). Immunodeficient nude mice start to devel p T 
cells after about 8 weeks of age and the maturation increases linearly thereafter. This 








CHAPTER II: MATERIALS AND METHODS 
Animals and Diet 
Forty seven-week-old and nine three-week-old NU/J homozygous male nude 
mice were obtained from the Jackson Laboratory (Bar Harbor, Maine) for Experiment 1 
and Experiment 2, respectively. The animals were randomly chosen into three groups
(see Table 1 for experimental design) and fed the AIN-93G Torula yeast purified rodent 
diet purchased from Dyets Inc (Bethlehem, Pennsylvania). Se-deficient (Se-) diet (see 
APPENDIX B for detailed composition) was the basal Torula yeast diet and contained 
less than 0.03 ppm selenium by analysis as certified by the company (APPENDIX ). Se-
adequate (Se+) diet was supplemented with 0.15 mg Se/kg (see APPENDIX C for 
composition) and Se-supranutritional (Se++) diet supplemented with 1 mg Se/kg as 
sodium selenate (see APPENDIX D for composition). The diet was stored at 4˚C. Mice 
were kept under pathogen-free conditions in a 12-hour dark/light cycle with controlled 
temperature of 24˚-25˚C and humidity between 40-65%. Animals were housed three to 
five mice per cage in disposable individually ventilated cages. The bedding was 
irradiated and mice had ad libitum access to food and sterilized water. The selenium-
modified diet was given throughout the whole course of the experiment, i.e. before and 















Number of animals (n) 
Length of time on diet 
(weeks) 
 





Se- 0.0 5 3 
28-32 11 Se+ 0.15 5 3 
Se++ 1.0 5 3 
 
Cell line 
All cell culture supplies were purchased from Mediatech, Inc unless otherwise 
specified. The PC-3 human prostate cancer cell line was obtained from American Type 
Culture Collection (Manassas, VA). This PC-3 cell line was originated from a 62-year-
old male taken from a bone metastasis with a stage IV adenocarcinoma. Cells wer  
grown and maintained in an incubator at 37°C, 5% CO2 in RPMI1640 medium 
containing 10% fetal bovine serum (FBS) (Aldrich-Sigma), 1% penicillin-streptomycin 
antibiotics and 1:5000 plasmocin (Invivogen) to prevent mycoplasma. Cells were 
subcultured in 1:4 ratio every 3-4 days when reaching 80% confluent.  
Blood collection 
Peripheral T cells were analyzed from blood collected from the tail of the animals. 
Animals were warmed up for five minutes under a heat lamp and placed in a restraining 
tube. The site of withdrawal was disinfected with alcohol before making a small cut with 
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a scalpel about 1/3 distance down from the top of the tail. Five drops (approximately 100 
µl in total) of blood were collected into blood collection tubes containing heparin to 
prevent coagulation. T cell analysis of xenografted animals was performed at baseline 
(day before xenograft), day 9, 19, 34 and 47 for experiment 1. T cell analysis for 
experiment 2 was done only at termination, day 46. 
Human tumor xenograft 
To prepare cells for inoculation, cells were harvested from passage 23 to 26 cells. 
After trypsinization, cells were counted by the use of disposable hemocytometer (IN 
CYTO, C-chip, SKC).  Each large flask (175 cm2) grown to 100% confluency yielded an 
average of 1x107 cells. After counting, cells were centrifuged at 500 x g for 5 min. Cells 
were resuspended with 10 mL SFM and centrifuged again.  After removing the 
supernatant, cells were resuspended  and 0.5 ml of cells in media were added to cold 0.5 
ml MatrigelTM  Basement Membrane Matrix (BD Biosciences, Cat.#356234) on ice, 
mixed with prechilled pipette tips and 100 µl aliquoted into eppendorf tubes on ice. Right 
before inoculation the mixture was drawn into syringes and injected subcutaneously on 
each side of shoulder blade (left or right dorsal thoracic region). Each injectio  contained 
2 x 106 cells for Experiment 1 and 8  x105 cells for Experiment 2. The size of the tumor 
was measured every other day using a plastic ruler. Length (L), width (W) and height (H) 
were measured for 6-7 weeks and the volume estimated using the following formula: W x 
L x H x 0.5236 (mm3) (Lee, Chun et al. 2006). At the termination of the experiments 
mice were euthanized using CO2, tumors and organs harvested and washed in PBS, and 
terminal bleeding was performed by cardiac puncture with a 21gauge 1½ needle and 
collected into a 3 mL syringe. Blood was then transferred into an eppendorf tube with 
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heparin and kept on ice. Tumors and spleen were blotted dry and weighed. Small sections 
of heart, liver, kidney, tumor tissue, and one whole lung were fixed in 15 mL of freshly 
made 4% paraformaldehyde for 24 hours for histology processing. The remaining tissues 
and organs were flash frozen in liquid nitrogen and stored in -80˚C until further analyses.  
Analytical methods  
Whole blood was centrifuged at 12000 g for 10 minutes at 4˚C (Schweizer, 
Michaelis et al. 2004) and plasma collected by aspiration and stored at -80˚C until 
analysis. Plasma selenium content were analyzed by a hydride-generation atomic 
absorption spectrometry method (Davis, Zeng et al. 2002).   
Peripheral T cell phenotyping 
Circulating peripheral T cells from blood collected from the tail were stained with 
antibodies and analyzed by flow cytometry. The following antibodies conjugated to 
specific fluorophores were used: anti-CD4 (Percp), anti-CD8 (PE), anti-CD44 (APC), 
anti-CD25 (FITC), and anti-CD62L (pacific blue) (from Biolegend, San Diago, CA).The 
whole blood was incubated with antibodies for 30 minutes at 4˚C, then fixed with 4% 
paraformaldehyde for 15 minutes at 4˚C, and washed with staining buffer  (2% fetal calf 
serum in phosphate-buffered saline). Lysis buffer was used to lyse the red blood cells 
(NH4Cl, KHCO3, 0.25 M EDTA) at room temperature for 10 minutes. The cells were 
then centrifuged at 12000 g for 12 minutes and supernatant aspirated. The pellet was 
resuspended and washed with staining buffer and centrifuged at 12 000 g for 10 minutes. 
Cells were resuspended in 100 µl staining buffer. The samples were then analyzed by 
FACSCalibur flow cytometer (BD Bioscience) and FLOWJO software (BD Biosciences) 




Liver, kidney, heart, and lung, as well as tumor tissues fixed in 4% 
paraformaldehyde were submitted to histology laboratory (Histoserv, Germantown, MD) 
for tissue processing. Processed tissues were embedded in paraffin and sectioned on a 
microtome 5 µm thick. Sections were put on uncoated slides, stained with H&E stain 
(hematoxylin and eosin stain) and coverslipped. Slides with tumor tissue sections were 
examined and histopathologically evaluated by a Board-certified Veterinary Pathologist, 
Jerrold M. Ward, DVM, PhD, in the Histoserv, Inc. The evaluation was based on the 
presence or absence of inflammation, necrosis, and hyalinization. Grading was done 
using the following scale: +, minimal; ++, mild; +++, moderate; ++++ severe. 
Statistical analysis 
Statistical analysis of the data obtained from body weight, tumor volume 
estimation, tumor weight, and plasma selenium concentration were performed by Student 
t test analysis and Analysis of Variance (ANOVA) using GraphPad Prism 5.03 software. 
Tukey’s post-test was used to compare between groups. T cell profile data were graph d 
and analyzed using a two-tailed Student’s t est (GraphPad Prism 3.0 software). The 








CHAPTER III: ADULT NUDE MICE XENOGRAFT STUDY 
Effect of long-term dietary selenium-deficiency on body weight and survival in male 
nude mice  
Forty eight-week-old male nude mice were randomly selected into two dietary 
groups (selenium-adequate and selenium-deficient). Four weeks later, six or seven mice 
were randomly taken out of the two groups and assigned to a third dietary group 
(selenium-supranutritional). One mouse from the selenium-adequate group died within 
the first four weeks on the diet of unknown causes, most likely unrelated to the diet, and 
was removed from all data and analyses. All mice ate the same selenium-modified diets. 
Selenium–adequate diet (Se+) was supplemented with 0.15 ppm sodium selenate, which 
is at the nutritional range, and served as the control group. Selenium-deficient diet (Se-) 
is the basal Torula yeast diet without additional supplementation with selenium. The third 
group is the selenium-supranutritional diet (Se++) which was supplemented with 1 ppm. 
sodium selenate. The average amount of feed consumed per day per animal was observed
to be approximately 4 g. Based on this information, the selenium-deficient group 
consumed about 0.12 µg, selenium-adequate group 0.6 µg, and selenium-supranutritional 
group 4 µg of selenium per day. Assuming that the average body weight of nude mice is 
30 g, the equivalent amounts correspond to an average of 4 µg Se/kg body weight, 20 µg 
Se/kg body weight, and 130 µg Se/kg body weight in Se-, Se+, and Se++ dietary group, 
respectively. These calculations are summarized in Table 2. 
 Body weight was measured every week. The initial body weights at the age of 
nine weeks, ranged from 22 g to 32 g and the final weights at the age of ten months were 
in the range of 29.7 g to 34.7 g. Five fittest nude mice from each group were removed for 
28 
 
xenograft experiment after 5-6 months on the experimental diet and the body weights 
were recorded and analyzed separately. The mean body weights for nude mice in the 
control (selenium-adequate) group (32.97 ± 0.45g) compared to the selenium-deficient 
(30.90 ± 0.37g) and selenium-supplemented (31.68 ± 1.07g) groups were not 
significantly different (p = 0.10) among the three dietary groups after 7 to 8 m nths on 
the selenium-modified diet. The changes in body weights over time are shown in Figure
3. 
 The body weights of nude mice fed the selenium-deficient diet were marginally 
lower than the selenium-adequate or selenium-supranutritional groups. Based on these 
results, the selenium given at the three doses (0, 0.15, 1.0 mg Se/kg diet) did not have 
negative effect on the body weight for the length of time used in this study.  
Survival rate seemed to be effected by the selenium modified diet and is depicte  
in Figure 4. Selenium deficiency seems to have negative effect on survival of nude mice. 
Selenium deficiency can be induced after about eight weeks. The survival data were 
recorded for twelve months and all surviving animals were sacrificed at that point. The 
survival was lower in selenium-deficient mice compared to the other groups especially 
during the first nine months. Only 3/8 mice in the selenium-deficient group survived 
beyond twelve month compared to 6/8 on the selenium-adequate diet and 4/8 on the 





Table 2. Amounts of selenium in each dietary group based on an average of 4 g of food 
consumed by experimental animal per day with the average body weight of 30 g. The 
basal selenium-deficient, Torula yeast basal diet contains 0.03 ppm selenium by analysis. 
Dietary 
group 
ppm (mg Se/kg diet, by 
analysis) 
µg Se/4g diet µg Se/kg body weight 
Se- 0.03 0.12 4 
Se+ 0.18 0.6 20 
Se++ 1.03 4 130 
 


















Figure 3. Effect of long-term selenium supplementation on changes of the mean body 
weights of the male nude mice fed a  libitum selenium-modified AIN-93G purified 
rodent diet for 37 weeks. The five animals from each group chosen for Experiment 1 
(xenograft) were not included after 25 weeks on this graph. Those animals are presented 
separately in the Experiment 1 section. Se-, selenium deficient; Se+, selenium adequate; 
Se++, selenium supranutritional. Data are presented as mean ± SEM. SEM, standard 




























Figure 4. Effect of long-term supplementation of male nude mice with selenium on 
survival. Animals were fed ad libitum selenium-modified AIN-93G purified diet for 10 
months. Se-, selenium deficient; Se+, selenium adequate; and Se++, selenium 
supranutritional. 
Plasma selenium analysis of nude mice in xenograft Experiment 1 
Five mice from each group were chosen based on their weight and health status in 
order to increase chance of survival throughout the xenograft study. The average lif span 
of nude mice is much lower than the wild type mice due to their suppressed immunity. 
Animals with good health and of steady weight were chosen to minimize losing a subject 
during the experiment due to poor health. In order to induce severe deficiency, we 
allowed for 6 months on selenium-deficient diet. At the same time, this period was 
necessary for extrathymic T cell maturation. It has been observed that extrathymic T cell 
maturation increases with age in nude mice, especially a dramatic increase after 32 weeks 
of age (Kennedy, Pierce et al. 1992). At the time of administration of the xenograft, the 
31 
 
animals were 33 weeks of age. This age was chosen in order for the animals to satisfy 
two criteria: long-term selenium deficiency and increased extrathymic T cell maturation. 
The effect of selenium supplementation on selenium status was analyzed by measuring 
the plasma selenium concentrations for nude mice at 32 weeks on selenium-deficient and 
selenium-adequate diet at 28 weeks on selenium-supranutritional diet. The data for 
plasma selenium concentrations are in Table 3. The results of the mean plasma 
concentrations for each dietary group are shown in Figure 5. The mean plasma selenium 
concentration was 2.5- and 2.8-fold lower in the Se- group (143.4 ± 13.0 ng/ml) 
compared to Se+ (353.2 ± 52.7 ng/ml, p = 0.0048) and Se++ (400.6 ± 41.0 ng/ml, p =
0.0003) group, respectively. The difference between Se+ and Se++ group was not 
statistically significant (p=0.498). Plasma selenium concentrations were observed to 
increase with higher selenium content in the diet. 
Table 3. Plasma selenium concentrations (ng/ml, mean ± SEM, n = 5) of the 3 dietary 





























207 130 226 355 212 396 
209 145 227 406 236 324 
213 189 228 155 238 468 
214 143 229 465 240 515 



































Figure 5. Mean plasma selenium concentrations in the post-mortem nude mice after 
termination of the xenograft experiment. The mice were fed on the Torula yeast bas l diet 
(Se-) or the diet supplemented with 0.15 mg Se/kg feed (Se+) and 1 mg Se/kg feed 
(Se++) in the form of sodium selenate. The amount is expressed as mean ± SEM (n=5 
mice). 
Body weights of adult male nude mice during xenograft study 
The body weights of study animals were measured every other day. The initial 
body weights at the beginning of the xenograft experiment ranged from 29.5 g to 35.4 g 
and the final weights after 7 weeks were in the range of 26.7 g and 32.0 g. The mean 
body weights for nude mice in the control (selenium-adequate) group (28.7 ± 0.9 g), the 
selenium-deficient (29.1 ± 0.9 g) and the selenium-supranutritional (30.2  ± 0.6 g) groups
were not significantly different (p = 0.41) at the end of the study (40 weeks of age). The 
changes in the body weights over time are shown in Figure 6 and Figure 7. The mean 
body weights of study animals at baseline (32.0 ± 0.4 g, n = 15) compared to those at 
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termination (29.4 ± 0.5 g, n = 15) were significantly different (p = 0.0001). This result 
implies that the statistically significant decrease in body weights was due to the xenograft 
itself and not due to the selenium supplementation. To further investigate the effect of 
xenograft on the changes in body weights, age-matched nude mice fed the same diets for 
the same length of time were compared to the study mice and the data are shown in 
Figure 8. The mean body weights at 33 weeks (initial, 31.2 ± 0.5 g, n = 16) were not 
statistically different (p = 0.45) from the mean body weights at 40 weeks (final, 30.6 ± 
0.7 g, n = 16) of the age-matched control nude mice.  
 


















Figure 6. Changes in the mean body weights (g, mean ± S.E.M., n = 5) for adult male 
nude mice during the 7-week xenograft study. Se-, selenium-deficient; Se+, selenium-





Figure 7. Changes in the initial and final mean body weights (g, mean ± S.E.M., n = 5) of 
adult male nude mice during 7-week xenograft study. Se-, selenium-deficient; Se+, 






















Figure 8. Changes in the initial (age 33 weeks) and final (age 40 weeks) mean body 
weights (g, mean ± SEM, n = 5) of control age-matched adult male nude mice. Se-, 
selenium-deficient; Se+, selenium-adequate; Se++, selenium-supranutritio al. 




















Effect of selenium on tumor volume and tumor weight in adult male nude mice in 
xenograft Experiment 1 
 
Estimated tumor volume was plotted as a function of time (Figure 9). The 
experiment was terminated when the average estimated tumor volume reached the 
greatest difference between groups (46 days after inoculation). At that point, the weight 
of the dissected tumors was measured and the mean as well as total weight for each
dietary group were calculated and plotted as shown in Table 4 and depicted in Figure 10. 
Animals in selenium-deficient and selenium-adequate group were on the experimental 
diet for 25 weeks and in selenium-supranutritional group for 21 weeks prior to cancer cell 
inoculation. The experimental diet continued to be given during the 7 weeks of xenograft 
study. 2 x 106 cells of human prostate cancer of the cell line PC-3 were injected 
subcutaneously on either side of the shoulder blade of each experimental animal (2 
injections/mouse). The success of the xenograft was recorded as the incidence of tumor 
growth at site of injection and is reported in Figure 12. The xenograft had nearly 100% 
success rate (30/31). Selenium deficiency enhances the initial tumor growth in the first 4 
weeks, but did not impact on tumor growth thereafter. Supranutritional level of dietary 
selenium greatly suppressed the tumor growth at all stages of the xenograft study (Figure 
9). At day 45 of xenograft (the last day to measure volume before sacrificing 
experimental animals) the mean tumor volume was significantly lower in seleium-
supranutritional group compared to selenium-deficient group (p < 0.05) but not selenium-
adequate group due to large within-group variance (p = 0.09) (Figure 10).   
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The control/selenium-adequate group had the largest tumor growth but also the 
largest within-group variability. The tumor volume estimation is a great tool in 
monitoring the tumor growth progression and is only as accurate as the observer’s 
measurement abilities. Tumor weight measured in post-mortem samples is th refore more 
accurate and is useful to verify the tumor volume data.  
The mean tumor weights differed between groups: selenium-deficient (0.29 ± 
0.10 g), control/selenium-adequate (0.64 ± 0.38 g), and selenium-supranutritional (0.21 ± 
0.06 g). However, due to the great within-group variability in the control group, the 
differences were not statistically significant (p = 0.37). The difference i  tumor weight 
was evidenced from the total tumor weight depicted in Figure 11B. Table 4 gives a 
summary of the combined tumor weights for each animal as well as the mean ± S.E.M. 
and the total tumor weight figures. The total tumor weight in the control group (2.56 g) 
was 3- and nearly 2-fold greater than that in the selenium-supranutritional (0.83 g) or 
selenium-deficient (1.46 g) groups, respectively. In order to account for differenc s in 
body weight in mice bearing tumors, we also explored the effect of the tumor weight to 
body weight ratio and found that the difference between groups was not statistically 




Tumor volume: time course



















Figure 9. Effect of selenium-modified diet on changes in the mean tumor volume. 2 x 106
cells of the PC-3 cell line of human prostate cancer were subcutaneously injected in adult 
male nude mice. Se-, selenium deficient; Se+, selenium adequate; Se++, selenium 

































Figure 10. At day 45 of xenograft (the last day to measure volume before sacrificing 
experimental animals) the mean tumor volume was significantly lower in seleium-
supranutritional (Se++) compared to selenium-deficient (Se-) (p < 0.05) but not 











Table 4. Tumor weights data (g, mean ± SEM, n= 5) of the 3 dietary groups at 
termination (day 47 after inoculation) Tumor weight was calculated as total weight of 
multiple tumors per mouse, if more than one found. Se-, selenium deficient (0.03 ppm); 


























207 0.47 226 0.20 212 0.29 
209 0.59 227 ND 236 0.29 
213 0.22 228 0.63 238 0.23 
214 0.03 229 0.03 240 ND 
Total 1.46  2.56  0.83 
mean ± 
SEM 





























































Figure 11. Final mean tumor weight (A) and total tumor weight (B) at termination (day 
47 after inoculation) compared between dietary groups. The values are mean ± SEM, 










































Figure 12. Incidence of tumor growth at site of cancer cell inoculation for the first 3 
weeks of xenograft study in adult male nude mice. Se-, selenium deficient; Se+, selenium 
adequate; Se++, selenium supranutritional. Numbers in parentheses represent the number 





















Figure 13. Tumor to body weight ratio compared between dietary groups. The values are 
mean ± SEM, n=5. Tumor weight (TW) was calculated as total weight of multiple tumors 
per mouse and the body weight (BW) was the last recorded BW before sacrifice.  
 
It is interesting to note that one animal (ID #240) from the selenium-
supranutritional group grew 2 tumors of maximum estimated volume 70 and 40 mm3 but 
the tumors regressed and completely disappeared by week 5 and 6. Another animal (ID 
#227) from Se-adequate group grew 2 tumors of maximum estimated volume 20 and 45 
mm3 but the tumors regressed and were undetectable by week 3. 
Circulating peripheral lymphocyte analysis for adult male nude mice in control 
animals 
Preliminary B and T cell profiles were performed for 30-week-old nude mice that 
did not receive xenograft. Flow cytometric analysis was employed to separate and 
quantify T cell subsets. Wild type B6 mice served as the control since these mice have 
normal functional thymus. The results show that the T cell numbers are about ten times 
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lower in nude mice than in the control B6 mice, confirming that immune deficiency in 
nude mice is closely linked to T cells but not B cells. However, no significant differenc s 
were observed between the dietary groups (Figure 14). Surprisingly, B cells were found 
to be about 10% higher (P < 0.05), in nude mice than in the control B6 mice. B cells were 
also significantly lower in selenium-deficient (p < 0.05) and selenium-supranutritional (p 
close to 0.05) groups compared to selenium-adequate group (Figure 15). To further 
analyze the T cell phenotypes represented by CD3-expressing cells, CD4 and CD8 T cell 
subsets were measured and the results are depicted in Figure 16 and Figure 17. CD8 T 
cells were found in higher numbers than CD4 T cells. CD8 T cells were approximately 10 
times lower in nude mice than in the control B6 mice and did not differ significantly 
between dietary groups. CD4 T cells were observed to be 10-20% lower in nude mice 
than the control B6 mice. The CD4 T cell numbers were significantly lower in the 
selenium-adequate group compared to selenium-deficient group (p<0.05) but not 
selenium-supranutritional group. Both selenium-deficient and selenium-supranutritio al 
diets seemed to increase the CD4 T cell numbers. CD8 T cells did not seem to be affected




Figure 14. Percentage of total live T cells (CD3 positive) in 30-week-old nude mice with 
B6 wild type mice serving as control. Se-, selenium deficient; Se+, selenium adequate; 
Se++, selenium supranutritional. N=5 for all groups, except Se++ n=4 due to one sampl








 Figure 15. Percentage of total live B cells (CD220) in 30-week-old athymic nude mice 
with B6 wild type mice serving as control. Se-, selenium deficient; Se+, selenium 
adequate; Se++, selenium supranutritional. N=5. 
 
 
Figure 16. Percentage of live CD8+ cells (T cell subset) in 30-week-old nude mice with 
B6 wild type mice serving as control. Se-, selenium deficient; Se+, selenium adequate; 
Se++, selenium supranutritional. N=5 for all groups, except Se++ n=4 due to one sampl







Figure 17. A. Percentage of live CD4+ cells (T cell subset) in 30-week-old nude mice 
with B6 wild type mice serving as control. Se-, selenium deficient; Se+, selenium 
adequate; Se++, selenium supranutritional. N=5 for all groups, except Se++ n=4 due to 




In addition, the expression of CD62L cells, a homing to peripheral lymph nodes T 
cell receptor, was significantly lower in nude mice compared to B6 mice in both CD8 and 
CD4 T cells but was not significantly different between selenium dietary groups. CD4 T 
cells, in fact, expressed extremely low levels of CD62L (bellow 3%). Results are shown 
in Figure 18 and Figure 19. This could indicate a potentially low activation and ability to 
perform function, especially for CD4 T cells. On the contrary, CD44 expression was 
generally high in the CD4 and CD8 T cells. This result indicates memory-like phenotyp  
and could be involved in tumor immunity. 
 
 
Figure 18. Percentage of CD62L expression in CD8 T cells in 30-week-old nude mice 
with B6 wild type mice serving as control. Se-, selenium deficient; Se+, selenium 
adequate; Se++, selenium supranutritional. N=5 for all groups, except Se++ n=4 due to 





Figure 19. Percentage of CD62L expression in CD4 T cells in 30-week-old nude mice 
with B6 wild type mice serving as control. Se-, selenium deficient; Se+, selenium 
adequate; Se++, selenium supranutritional. N=5 for all groups, except Se++ n=4 due to 
one sample lacking sufficient events. 
Circulating peripheral lymphocyte analysis for adult male nude mice in xenograft 
Experiment 1 
 T cells were measured at baseline, day 9, 19, 34, and at termination of the 
xenograft experiment 1. The major phenotypes were CD4+ and CD8+ T cells. Expression 
of CD25 and CD44 was also measured and analyzed. Figure 20 summarizes the results 
for percent of CD4 positive live cells at the specified time points. Selenium status did not 
have significant effect on CD4 T cell maturation and the xenograft seemed to suppress 
these cells. However, as expected, the CD4 T cell numbers increased significantly with 
age of the animals as compared at baseline and at termination for all three dietary groups. 
Similarly, percent of circulating live CD8 positive T cells were analyzed at the 
specified time points during the xenograft and the results show a trend of decrease aft r 
exposure to tumor cells (Figure 21). CD8 T cells were slightly enhanced by high 
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selenium diet before the xenograft. Selenium-deficient diet also seemed to increase the 
CD8 T cells after the xenograft (day 47). Selenium-adequate diet resulted in lower CD8 T 
cells compared to selenium-deficient (p = 0.8) and selenium-supranutritional diet (p = 
1.2); however, the difference was only marginally significant. Figure 22 depicts both 
CD4 and CD8 T cells combined. The trend follows the previous result with no significant 
differences between dietary groups, but with significant increase in the CD4 and CD8 T 
cells when comparing baseline numbers to those at termination. 
 
CD4% of live cells
 Time course




















Figure 20. Mean percent peripheral live CD4 positive T cells measured at baseline, day 9, 
19, 34 and termination of xenograft experiment. N=5, mean ± SEM for each dietary 






Figure 21. Mean percent peripheral live CD8 positive T cells measured at baseline, day 9, 
19, 34 and termination of xenograft experiment. N=5, mean ± SEM for each dietary 


















































Figure 22. Mean percent peripheral live CD4 and CD8 positive T cells together measured 
at baseline, day 9, 19, 34 and termination of xenograft experiment. N=5, mean ± SEM for 
each dietary group.  Se-, selenium deficient; Se+, selenium adequate; Se++, sel nium 
supranutritional. 
Expression of CD25 is a measure of activity and ability to perform functions of T 
cells. A marginally significant difference was observed on day 9 of the xenograft in 
CD25+CD4+ cells (p = 0.1) between selenium-adequate and selenium-supranutritional 
groups. Selenium-adequate group had lower CD25 expression than selenium-deficient 
and selenium-supranutritional groups. The expression of CD25 in either CD4 or CD8 T 




Figure 23. Mean percent CD25+CD4+ cells measured at day 9 of xenograft experiment. 
N=5, mean ± SEM for each dietary group. Se-, selenium deficient; Se+, selenium 
adequate; Se++, selenium supranutritional. 
 
Since spleen is the main site for T cell accumulation, the weight of the organ 
could be a relative indicator of the amount of T cells in the body. The mean spleen weight 
for each dietary group was calculated and is shown in Figure 24. The difference in spleen 
weight was not significant between the dietary groups. However, correlation between he 
weight of the spleen and CD4 positive T cells indicated strongly positive result (Pearson r 
= 0.83, p = 0.0001) (Figure 25). The absolute numbers of T cells isolated from the spleen 
and the T cell numbers measured in the periphery as measured in the blood are closely 
















































Figure 24. Mean weight of spleen for adult male nude mice comparing the three selenium 






Correlating CD4 T cells and
weight of spleen


















Figure 25. Correlation between CD4 T cell numbers and weight of spleen for adult male 
nude mice. N=15, Pearson r = 0.83, p = 0.0001. 
Histopathology of tumor tissues for adult nude mice 
 
Histopathology was evaluated using H&E stained tumor and tissue sections fixed 
in paraformaldehyde and embedded in paraffin.  The results are summarized in Table 5
and representative pictures are shown in Figure 26. The grading was done using the 
following scale: +, minimal; ++, mild; +++, moderate; ++++ severe by a board certified 
pathologist (Jerrold M. Ward, DVM, PhD). Of note, one tumor from the selenium-
supranutritional group was hyalinized. The hyalinized tumor indicates that the tumor 
regressed and tumor cells may have undergone necrosis or apoptosis. The 
histopathological results indicate inflammation in necrotic lymphocytes and tumor cells.  
Tumors coming from the selenium-supranutritional group were found to have less 
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inflammation. Inflammation promotes tumor growth. This result is in accordance with the 
observation that the selenium-supranutritional group had the smallest tumors. 
Table 5. Findings of histopathology for tumor sections from adult nude mice 
Dietary 
group  Tag Inflammation Tumor Necrosis 
Se-  205 ++ + 
 207 ++ + 
 209 + + 
 213 ++ ++ 
 214 ++ + 
Se+  216 - - 
 226 + ++ 
 228 + ++ 
 229 ++ - 
Se++  211 - + hyalinized 
 212 - - 
 236 ++ - 




Figure 26. Representative hematoxylin and eosin (H&E) stained slides of tumor tissue 








 YOUNG NUDE MICE XENOGRAFT STUDY 
 
After performing the first experiment with adult nude mice, we sought 
comparison of the data to young-aged subjects. Experiment 2 was therefore performed to 
mirror Experiment 1 with some minor changes that will be highlighted in this section of 
the thesis.  
Body weight of young male nude mice on selenium-modified diet before and during 
xenograft study 
 
Nine three-week-old male nude mice were randomly selected and were fed with a 
Se- basal diet, or the diet supplemented with 0.15 (Se+, adequate) or 1 (Se++, 
supranutritional) mg Se/kg as sodium selenate. Body weight was measured every week. 
The initial body weights at 3 weeks of age ranged from 9.2 g to 13.8 g and the final 
weights at the age of 14 weeks were in the range of 26.4 g to 32.5 g. The mean body 
weights for nude mice in the control (selenium-adequate) group (29.7 ± 1.4 g) compared 
to the selenium-deficient (29.6 ± 0.9 g) and selenium-supranutritional (27.2 ± 0.5 g) 
groups were not significantly different (p = 0.21) among the three dietary groups after 10 
weeks on the selenium-modified diet. The changes in body weights over time are shown 
in Figure 27. The body weights of nude mice fed the selenium-supranutritional diet were 
marginally lower than the selenium-adequate or selenium-deficient groups. Based on 
these results, selenium given at the three doses (0, 0.15, 1 mg Se/kg feed) did not have 
negative effect on the body weight for the length of time used in this study. All nude mice 


























Figure 27. Effect of dietary selenium on changes of the mean body weights of young 
male nude mice fed ad libitum selenium-modified AIN-93G purified rodent diet for11 
weeks. Se-, selenium deficient; Se+ ,selenium adequate; Se++, selenium supranutritional. 
Data are presented as mean ± SEM, n = 3. SEM = standard error of the mean. 
 
The nude mice in this experiment were gaining weight until about 8 weeks of age, 
which is equivalent to 5 weeks on the experimental diet. After that point, the mice were 
assumed to have reached their maximum weight. In order to examine the effect of th  
xenograft itself on the body weight, the initial body weight was established as the 
maximum weight reached at 5 weeks on the diet (8 weeks of age) because the young 
mice were still gaining weight after xenograft. This corresponds to one week after 
xenograft administration. The xenograft study was carried out for 7 weeks to be 
consistent with experiment 1. Figure 28 and Figure 29 show the graphed results of 
changes in the mean body weights. The body weights of the animals were measured 
58 
 
every other day. The initial body weights at baseline of the xenograft experiment (week 
7) ranged from 28.8 g to 32.9 g and the final weights at week 14 were in the range of 26.4 
g and 32.5 g. The mean body weights for nude mice in the control (selenium-adequate) 
group (29.7 ± 1.4g) compared to the selenium-deficient (29.6 ± 0.9g) and selenium-
supplemented (27.2 ± 0.5 g) groups were not significantly different (p = 0.21) among the 
three dietary groups after 10 weeks on the selenium-modified diet (14 weeks of age). 
However, the mean body weights of study animals at baseline (31.2 ± 0.5 g, n = 9) 
compared to at termination (28.8 ± 0.7 g, n = 9) were significantly different (p = 0.01). 
This result implies that the statistically significant decrease in body weights was due to 






























Figure 28. Changes in the mean body weights (g, mean ± SEM, n = 3) for young male 
nude mice during 7-week xenograft study. Se-, selenium deficient; Se+, selenium 






























Figure 29. Changes in the initial and final mean body weights (g, mean ± SEM, n = 3) of 
young male nude mice during 7-week xenograft study. The initial weight was determined 
by the maximum body weight reached at week 1 after inoculation. Se-, selenium 
deficient; Se+, selenium adequate; and Se++, selenium supranutritional. 
 
Plasma selenium analysis of young male nude mice in xenograft Experiment 2 
 
The effect of selenium supplementation on body selenium status was analyzed by 
measuring the plasma selenium concentrations for nude mice at 11 weeks on the Se-
modified diets. The data for plasma selenium concentrations are in Table 6. The results of 
the mean plasma concentrations for each dietary group are shown in Figure 30. The mean 
plasma selenium concentration was nearly 4-fold lower in the selenium-deficient group 
(90.0 ± 11.0 ng/ml) compared to selenium-adequate (348.7 ± 18.0 ng/ml, p = 0.0003) and 
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selenium-supranutritional (340.3 ± 12.5 ng/ml, p = 0.0001) group, respectively. The 
difference between selenium-adequate and selenium-supranutritional group was not 
statistically significant (p=0.723).  
Table 6. Plasma selenium concentrations (ng/ml, mean ± SEM, n = 3) for young male 
nude mice in the 3 dietary groups at termination (10 weeks on the diet). 
































262 112 266 362 268 331 
270 79 267 371 269 325 



































Figure 30. Mean plasma selenium concentrations for young male nude mice after 14 
weeks on diet containing 0.03 ppm (Se-), 0.15 ppm (Se+), and 1 ppm (Se++) selenium in 
the form of sodium selenate. The amount is expressed as mean ± SEM (n=3 mice). 
 
Effect of selenium on tumor volume and tumor weight in young male nude mice in 
xenograft Experiment 2 
Estimated tumor volume was plotted as a function of time (Figure 31). Consistent 
with xenograft study 1 (46 days after inoculation), mice in Experiment 2 were terminated 
7 weeks after the xenograft. At that point, the weight of the dissected tumors was 
measured and the mean as well as total weight for each dietary group were calculated and 
plotted as shown in Table 7 and depicted in Figure 32. All animals were on the 
experimental diet for the same amount time (4 weeks) prior to cancer cell inoculati n. 
The experimental diet continued to be given during the 7 weeks of the xenograft study. 8 
x 105 cells of human prostate cancer of the cell line PC-3 were injected subcutaneously 
on either side of the shoulder blade of each experimental nude mouse. We injected less 
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PC-3 cells in Experiment 2 (8 x 105 vs.  2 x 106) because young nude mice have stronger 
immune system as no extrathymic T cell maturation occurs yet.  
The success of the xenograft was recorded as the incidence of tumor growth at 
site of injection and is reported in Figure 34. Selenium deficiency seemed to enhance the 
initial tumor growth, especially during the first few weeks. Selenium supplementation, on 
the other hand, seemed to delay tumor growth in the initial stages. The xenograft had a 
100% success rate (20/20). Selenium deficiency seemed to enhance tumor growth in the 
first week, but did not enhance tumor growth, which was measured by estimating the 
volume, throughout the total time course of the xenograft experiment. Contrary to 
expectation and what was observed in experiment 1, supplementation with 1 mg Se/kg 
diet, did not suppress the tumor growth at all; rather, it enhanced tumor growth (Figure
31, Figure 32, Figure 33, and Table 7). Interestingly, the control/selenium-adequate group 
that had the largest tumor growth in the first experiment, had the smallest tumor volume 
and weight. The mean tumor weights did not differ significantly (p = 0.47) between 
groups: selenium-deficient (1.2 ± 0.1g), control/selenium-adequate (1.1 ± 0.6 g), and 
selenium-supranutritional (1.5 ± 0.1 g). The difference in tumor weight can be visually 
seen from the total tumor weight depicted in Figure 32B. Table 7 gives a summary of the 
combined tumor weights for each experimental rodent as well as the mean ± S.E.M. and 
the total tumor weight figures.  
A nearly 2- and 1.6-fold decrease was observed in the total tumor weight between 
the control group (2.3 g) and the selenium-supranutritional (4.5 g) and selenium-deficient 
(3.7 g) groups, respectively. We also explored the effect of the tumor weight to body 
weight ratio and found that the difference between groups was not statistically 
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significant, however the difference between Se- and Se++ was marginally significant (p = 



























Figure 31. Effect of selenium-modified diet on changes in the mean tumor volume. 8x105 
cells of the PC-3 cell line of human prostate cancer were subcutaneously injected in 
young male nude mice. Se-, selenium deficient; Se+, selenium adequate; Se++, sel nium 










Table 7. Tumor weights data (g, mean ± SEM, n= 3) for young nude mice in the 3 dietary 
groups at termination (day 46 after inoculation) Tumor weight was calculated as otal 
weight of multiple tumors per mouse, if more than one found. Se-, selenium deficient 
(0.03 ppm); Se+, selenium adequate (0.15 ppm); Se++, selenium supranutritional (1 ppm) 






















262 1.15 266 1.75 268 1.40 
270 1.42 267 0.53 269 1.41 
Total 3.70  2.28  4.52 
























































Figure 32. Final average tumor weight (A) and total tumor weight (B) at termination (day 
46 after inoculation) for young male nude mice compared between dietary groups. A. The 
values are mean ± SEM, n = 3. Tumor weight was calculated as total weight of muliple 






















Figure 33. Tumor to body weight ratio compared between dietary groups. The values are 
mean ± SEM, n=3. Tumor weight was calculated as total weight of multiple tumors per 














































Figure 34. Incidence of tumor growth at site of cancer cell inoculation for the first 3 
weeks of xenograft study in young male nude mice. Se-, selenium deficient; Se+, 
selenium adequate; Se++, selenium supranutritional. Numbers in parentheses represnt 
the number of tumor inoculations per group. 
It is interesting to note, that one animal in the control (Se+) group grew 3 tumors 
for 3-4 weeks and then all 3 tumors regressed, one by one, to undetectable size and were 
not even found during dissection. The estimated largest volumes for these tumors were 4, 
40 and 70 mm3.  
 
Circulating peripheral lymphocyte analysis for young male nude mice in xenograft 
Experiment 2 
 
T cells were measured only at termination as it was assumed that the numbers of 
circulating peripheral T cells were too low to be detectable in significat amounts for the 
young nude mice.  The results for young nude mice were inconsistent with what was seen 
in adult nude mice, when analyzing the effect of dietary selenium dose on T cell 
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maturation. The percent of live CD8+ cells in young nude mice was highest for the 
selenium-supranutritional group but there was also very high within-group variability so 
difference was not significant (Figure 35). The mean percent of  CD4 T cells in selenium-
supranutritional group, on the other hand, was significantly lower than in selenium-
adequate group (p < 0.05) and marginally lower than selenium-deficient group (p = 0.9). 
This result is shown in Figure 36. Figure 37 and Figure 38 depict the combined CD4+ 

























Figure 35. Percentage of live CD8+ T cells in 14-week-old athymic nude mice. Se-, 
































Figure 36. Percentage of live CD4+ cells in 14-week-old athymic nude mice. Se-, 

































Figure 37. Percentage of live CD8+ and CD4+ cells combined together in 14-week-old 
athymic nude mice. Se-, selenium deficient; Se+, selenium adequate; Se++, selenium 
























Figure 38. Ratio of CD8/CD4 T cells in 14-week-old athymic nude mice. Se-, selenium 




Since spleen is the main site for T cell accumulation, the weight of the organ 
could be a relative indicator of the amount of T cells in the body. The mean spleen weight 
for each dietary group was calculated and is shown in Figure 39. Correlation between the 
weight of the spleen and CD4 positive T cells indicate fairly positive result (Pearson r = 
0.62, p = 0.07) (Figure 40). 
 























Figure 39. Mean weight of spleen for young male nude mice in comparing the three 






Correlating CD4 T cells and
the weight of spleen





















Figure 40. Correlation between CD4 T cell numbers and weight of spleen for young male 
nude mice. N=9, Pearson r = 0.62, p = 0.07. 
 
Histopathology of tumor tissues for young nude mice 
 
Histopathological evaluation was done on H&E stained tumor tissue sections 
fixed in paraformaldehyde and embedded in paraffin.  The results are summarized in 
Table 8. The grading was done using the following scale: +, minimal; ++, mild; +++, 
moderate; ++++ severe. A large number of the tumors had hyalinized stroma, an aberr t 
deposition of basement membrane material produced by tumor cells. The hyalinized 
tumor indicates that the tumor regressed and tumor cells may have undergone necrosis or 
apoptosis. Representative pictures from each group are shown in Figure 41. 
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Figure 41. Representative pictures of hematoxylin and eosin (H&E) stained tumor tissue 










CHAPTER V: DISCUSSION 
 
These experiments were undertaken in order to determine the effect of dietary
supplementation with selenium on T cell immunity in response to human prostate cancer 
xenograft in male nude mice. Male nude mice animal model was applied in this study 
because they do not reject human xenografts (Manning, Reed et al. 1973) and because 
prostate cancer is a malignancy afflicting men only.  
Prior to this work, no studies have looked at chemopreventive role of selenium in 
conjunction with T cell immunity in nude mice bearing xenografted tumors. To date, few 
studies have been conducted to explore the effect of various selenium compounds in nude 
mice bearing tumor xenograft coming from various human tissues (Lin, Boylan et al. 
1991; Li, Lee et al. 2008; Yang, Huang et al. 2009). Here, we also aimed to explore the 
efficacy of selenium, at higher than nutritional dose, as a potential chemopreventiv  agent 
against prostate cancer.  Conflicting results have been reported from two large 
intervention studies: the NPC trial that employed supplementation with 200 µg of 
selenium as enriched yeast and showed significant decrease in some cancers, especially 
prostate cancer (Duffield-Lillico, Reid et al. 2002); whereas the SELECT trial that used 
supplementation with 200 µg of selenium as selenomethionine failed to show decrease in 
prostate cancer incidence (Lippman, Klein et al. 2009).  
In vivo studies of selenium as anticarcinogenic agent also show conflicting results. 
Study by Lin et al showed no effect of diet deficient in selenium or supplemented with 4
mg Se/kg (as sodium selenite) for 4 weeks on human mammary tumor xenograft in nude 
mice (Lin, Boylan et al. 1991). The tumor xenograft result for adult nude mice in this 
study is in accordance with other studies that used organic or inorganic forms of selenium 
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(Li, Lee et al. 2008) and we confirmed the anti-tumorigenic efficacy of sodium selenate 
at the supranutritional level but failed to show the same effect in young subjects. Similar 
to the result for young nude mice in this study, Finley and Davis showed an increase in 
chemically-induced aberrant crypt and aberrant crypt foci in rats depleted and then 
repleted with sodium selenate at 0.1 ppm and 1 ppm even more, compared to no addition 
(Finley and Davis 2001). 
To our knowledge, no data is available concerning the effect of long-term dietary 
supplementation with sodium selenate on human prostate cancer xenograft in nude mice. 
The long-term supplementation was chosen to allow for observation of possible adverse 
effects of supranutritional dose supplementation as well as deficiency.  It also allowed for 
extrathymic T cell maturation, which usually peaks at around 32 weeks of age in nude 
mice, so that the effect of dietary selenium dose on the maturation and activity could be 
examined (Kennedy, Pierce et al. 1992).   
Supplementation with high selenium has opposing effect on prostate tumor xenograft 
in adult versus young nude mice 
The most interesting result was observed from high supplementation of selenium 
on tumor growth in adult versus young nude mice. Why did selenium supplementation at 
the supranutritional level suppress tumor formation in adult nude mice but promoted 
tumor growth in young nude mice? In order to attempt to answer this question, it is 
important to look at the differences in plasma selenium levels and T cell phenotypes. In 
adult nude mice, the tumor volume/weight overall was 2-3-fold lower than in the young 
nude mice (Figure 10, Figure 11, Figure 31, Figure 32). Although, adult mice were on 
selenium-modified diet 6 months longer than the young mice, plasma selenium 
concentrations were similar and the differences between dietary groups were comparable 
76 
 
(Figure 5 and Figure 30). So the difference in tumor size in the young versus adult 
animals could be more likely attributed to the effect of T cell immunity. The T cell 
(CD4+CD8) maturation increased with the age of the animals as seen in the graph bellow 
(Figure 42), from bellow 0.5% at 14 weeks to 3-5% at 33 weeks to 10-15% of CD4+CD8 
percent live cells at 40 weeks of age. When selenium-supranutritional dietary groupsa e 
evaluated closely, there are differences between the numbers of CD4+ T cells of adult 
and young nude mice. In fact, the CD4 + T cells in young nude mice are significantly 
lower compared to the other selenium dietary groups (Figure 36) and the tumor 
volume/weight are significantly higher. From this observation, it seems that high dietary 
selenium causes a decrease in CD4 T cells which may be associated with tumor 
formation in young nude mice. Conversely, why does high selenium in older nude mice 
not suppress CD4 T cells? Is it possible that other functional T cells are stimulated in the 
older mice that are lacking in the young ones? The pathway or mechanism to explain this 
observation is beyond the scope of this study and could be the groundwork for future 
research. Selenium has been shown to affect cell-mediated immunity. Specifically, 
combined selenium -vitamin E deficient diet depressed T-lymphocyte-mediated 
cytotoxicity in rats after 7 weeks on diet (Meeker, Eskew et al. 1985). Thus we could 
speculate, that the toxic effect of selenium could be compromised in young nude mice 
whose T-lymphocytes are mostly immature and non-functional. This phenomenon, in 
turn, could explain why the older nude mice, with increased T cell maturation, exhibit the 




























Figure 42. T cell maturation increases with age 
Plasma selenium concentrations are not related to tumor growth in adult and young 
nude mice supplemented with 0, 0.15 and 1 mg Se/kg diet 
Although, dietary supplementation with sodium selenate was 5- and 35-fold 
higher in selenium-adequate and selenium-supranutritional diet, respectively, compared 
to selenium-deficient diet, plasma selenium levels of adult mice from selenium-deficient 
group were 40% of those of selenium-adequate and 35% of those mice in selenium-
supranutritional group (Figure 5). In young mice from selenium-deficient group, plasma 
levels were 25% of those mice from both of the supplemented groups (Figure 30). Thus, 
it seems that plasma selenium levels are related to age and there seems to be a cut off 
value at which plasma selenium does not increase with increasing dietary intake. Similar 
to our study, plasma selenium values of 0.9, 5.1, and 4.5 µmol/L were observed by Cheng 
et al, where mice were fed selenium deficient, adequate, excessive diet containing < 0.02, 
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0.5, 3.0 mg Se/kg feed, respectively, as sodium selenite for 6 weeks. The plasma 
selenium concentrations in our study are very similar even with lower adequate (0.15 
ppm) and supranutritional (1.0 ppm) doses. Specifically, in adult nude mice plasma 
selenium values were 1.8 µmol/L (143 ng/ml), 4.5 µmol/L (353 ng/ml) and 5.0 µmol/L 
(400 ng/ml) and in young mice 1.4 µmol/L (90 ng/ml), 4.4 µmol/L (348 ng/ml) and 4.3 
µmol/L (340ng/ml) (Cheng 1998). The explanation could be that selenium excretion also 
increases with increased dietary intake but is reduced under selenium deficient conditions 
to preserve body’s reserves (Levander 1986). Therefore, plasma selenium concentration 
values in mice on selenium-adequate diet are very similar to values of mice on selenium-
supranutritional diet in both studies. This observation leads to another question. Why 
does such small difference in plasma selenium (adequate vs. supranutritional) give such 
drastic result in tumor growth suppression in adult nude mice? First, Finley and his group 
showed that high-selenium broccoli was the most efficacious against colon aberrant 
crypts in spite of having the lowest bioavailability (measured as GPx activity) when 
compared to other selenium compounds (Finley and Davis 2001). Next, selenium can act 
through selenoproteins, which have antioxidant role, and through intermediary 
metabolites at higher doses, which are toxic and capable of inducing DNA damage 
leading to cell death or senescence (Combs and Gray 1998; Drake 2006; Wu, Kang et al. 
2010). It appears that in our study selenium-deficient and –adequate levels did not have 
effect on tumorigenesis but the higher selenium-supranutritional level was sufficiently 
high to have a significant effect on tumor growth suppression. From our knowledge of 




Selenium-deficient status does not have effect on tumor growth  
It was observed, that selenium-deficient diet greatly reduces plasma selenium 
concentrations. This result has been reported in other studies as well (Burk, Norsworthy 
et al. 2006; Wang, Wu et al. 2009). However, selenium deficiency did not significantly 
enhance tumor growth in either adult or young animals. This result has been observed 
elsewhere in a similar model using dietary supplementation with selenite for 2 months 
and human mammary tumor xenograft in nude mice for 4 weeks and measuring GPx 
activity instead of plasma selenium for indication of selenium status (Lin, Boylan et al. 
1991). Although selenium-deficient diet did not enhance final tumor volume and tumor 
weight, it did promote the initial tumor growth and incidence (Figure 12 and Figure 34) 
in both age groups. Selenoprotein activity is affected by selenium-deficient status (Combs 
and Gray 1998; Driscoll and Copeland 2003). Therefore, it is possible that the antioxidant 
activity of selenoproteins plays role during the initial stage of tumorigenesis as seen in 
our results of tumor growth and incidence.  
Limitations and Strengths of the study 
This study could have been improved by measuring T cell profiles at baseline in 
addition to at termination for young nude mice xenograft experiment in order to compare 
the effect of short-term selenium supplementation on T cell maturation and activation n 
younger subjects. Measuring the selenium content in the tumor tissue in addition to in the 
plasma only, would also provide valuable information regarding the distribution of 
selenium during tumorigenesis. However, the tumor tissues collected were not 
sufficiently large to perform this analysis on all samples. 
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On the other hand, this study has some noteworthy strengths. Nude mice have 
been shown to be good models for cancer studies. Mice also develop cancer like humans 
do. The use of older mice allowed for a good mimic of practical situation: the incidence 
of cancer increases with age. The supranutritional dose (1 ppm) allowed us to study the 
long-term effect of supplementation with higher selenium without the toxic effects that 
could be associated with higher doses. And at the same time, this period was necessary 



















SUMMARY AND IMPLICATIONS 
 
Selenium given as sodium selenate at the three doses (0, 0.15, 1 mg selenium/kg 
diet) does not have negative effect on the body weight for the length of time used in this 
study. However, long-term selenium deficiency seems to have negative effect on survival 
of nude mice. Plasma selenium increases with higher dietary intake but does not differ 
significantly between adequate and supranutritional level. Tumor xenograft signi icantly 
decreased body weight of mice regardless selenium supplementation.  
Dietary supplementation with sodium selenate for 8 months at the supranutritional 
level suppresses tumor formation in adult nude mice but promotes tumor growth in young 
nude mice. Tumor size was greatly affected by the age of the animals and could be likely 
attributed to the effect of T cell immunity. The T cell (CD4+CD8) maturation increased 
with the age of the nude mice. After xenograft, dietary selenium status does not affect 
levels of CD4 and CD8 T cells in adult nude mice in Experiment 1, while high selenium 
resulted in significant decrease in CD4 T cells in young nude mice in Experiment 2.  
Taken together, there is an opposing role of excessive selenium on tumor xenograft 
development in adult and young nude mice carrying differential T cell profiles. These 
results indicate that the anticarcinogenic activity of selenium could be corr lated with the 
age of the subject. It seems that with age, selenium plays more significant role i  tumor 
growth suppression, whereas in the young mice, selenium seems to promote 
tumorigenesis. The importance of age considerations and the appropriate dose as well as 









APPENDIX B. Composition of modified AIN-93G Torula yeast diet for selenium 
studies in rodents to provide selenium deficient diet. Dyet # 116053 
 
Ingredients kcal./gm grams/kg kcal./kg 
Torula Yeast 3.59 300 1077 
Sucrose 4 100 400 
Corsntarch 3.6 318.861 1147.8996 
Dyetrose 3.8 107 406.6 
L-Cystine 4 3.52 14 
Cellulose, microcrystalline 0 50 0 
Soybean Oil 9 70 630 
t-Butylhydroquinone 0 0.014 0 
Mineral Mix#216269, Rx 0.34 35 11.9 
Vitamin Mix #310025 3.87 10 38.7 
L-Methionine 4 2.91 11.64 
L-Tryptophan 4 0.16 0.64 
Choline Bitartrate 0 2.5 0 


















APPENDIX C. Composition of modified AIN-93G Torula yeast diet for selenium 
studies in rodents to provide 0.15 ppm selenium as sodium selenate. Dyet # 116053 
 
Ingredients kcal./gm grams/kg kcal./kg 
Torula Yeast 3.59 300 1077 
Sucrose 4 100 400 
Corsntarch 3.6 318.861 1147.8996 
Dyetrose 3.8 107 406.6 
L-Cystine 4 3.52 14 
Cellulose, microcrystalline 0 50 0 
Soybean Oil 9 70 630 
t-Butylhydroquinone 0 0.014 0 
Mineral Mix#216269, Rx 0.34 35 11.9 
Vitamin Mix #310025 3.87 10 38.7 
L-Methionine 4 2.91 11.64 
L-Tryptophan 4 0.16 0.64 
Sodium Selenate Premix (10 mg/g) 4 0.035 0 
Choline Bitartrate 0 2.5 0 
















APPENDIX D. Composition of modified AIN-93G Torula yeast diet for selenium 
studies in rodents to provide 1 ppm selenium as sodium selenate. Dyet # 116054 
 
Ingredients kcal./gm grams/kg kcal./kg 
Torula Yeast 3.59 300 1077 
Sucrose 4 100 400 
Corsntarch 3.6 318.861 1147.8996 
Dyetrose 3.8 107 406.6 
L-Cystine 4 3.52 14 
Cellulose, microcrystalline 0 50 0 
Soybean Oil 9 70 630 
t-Butylhydroquinone 0 0.014 0 
Mineral Mix#216269, Rx 0.34 35 11.9 
Vitamin Mix #310025 3.87 10 38.7 
L-Methionine 4 2.91 11.64 
L-Tryptophan 4 0.16 0.64 
Sodium Selenate Premix (10 mg/g) 4 0.25 0 
Choline Bitartrate 0 2.5 0 



























Allmang, C. and A. Krol (2006). "Selenoprotein synthesis: UGA does not end the story." 
Biochimie 88(11): 1561-1571. 
Arthur, J. R., R. C. McKenzie, et al. (2003). "Selenium in the immune system." Journal 
of Nutrition 133(5): 1457S-1459S. 
Bai, Y., Q. Q. Mao, et al. (2010). "Resveratrol induces apoptosis and cell cycle arrest of 
human T24 bladder cancer cells in vitro and inhibits tumor growth in vivo." 
Cancer Science 101(2): 488-493. 
Bartkova, J., N. Rezaei, et al. (2006). "Oncogene-induced senescence is part of the 
tumorigenesis barrier imposed by DNA damage checkpoints." Nature 444(7119): 
633-637. 
Brown, K. M., Arthur, J. R. (2001). "Selenium, selenoproteins and human health: a 
review." Public Health Nutrition 4(2B): 593-599. 
Burk, R. F. (1991). "MOLECULAR-BIOLOGY OF SELENIUM WITH 
IMPLICATIONS FOR ITS METABOLISM." Faseb Journal 5(9): 2274-2279. 
Burk, R. F., K. E. Hill, et al. (2001). "Plasma selenium in specific and non-specific 
forms." Biofactors 14(1-4): 107-114. 
Burk, R. F., B. K. Norsworthy, et al. (2006). "Effects of chemical form of selenium on 
plasma biomarkers in a high-dose human supplementation trial." Cancer 
Epidemiology Biomarkers & Prevention 15(4): 804-810. 
Carlson, B. A., M. H. Yoo, et al. (2009). "Selenoproteins regulate macrophage 
invasiveness and extracellular matrix-related gene expression." Bmc Im unology 
10. 
Chaplin, D. D. (2010). "Overview of the immune response." Journal of Allergy and 
Clinical Immunology 125(2): S3-S23. 
Cheng, W. H., Combs G. F., Lei X. G. (1998). "Knockout of cellular glutathione 
peroxidase affects selenium-dependent parameters similarly in mice fed adequate 
and excessive dietary selenium." Biofactors 7(Number 4): 311-321. 
Clark, L. C. (1985). "THE EPIDEMIOLOGY OF SELENIUM AND CANCER." 
Federation Proceedings 44(9): 2584-2589. 
Combs, G. F. and S. B. Combs (1984). "THE NUTRITIONAL BIOCHEMISTRY OF 
SELENIUM." Annual Review of Nutrition 4: 257-280. 
88 
 
Combs, G. F. and W. P. Gray (1998). "Chemopreventive agents: Selenium." 
Pharmacology & Therapeutics 79(3): 179-192. 
Davis, C. D., H. W. Zeng, et al. (2002). "Selenium-enriched broccoli decreases intestinal 
tumorigenesis in multiple intestinal neoplasia mice." Journal of Nutrition 132(2): 
307-309. 
Drake, E. N. (2006). "Cancer chemoprevention: Selenium as a prooxidant not an 
antioxidant." Medical Hypotheses 67(2): 318-322. 
Driscoll, D. M. and P. R. Copeland (2003). "Mechanism and regulation of selenoprotein 
synthesis." Annual Review of Nutrition 23: 17-40. 
Duffield-Lillico, A. J., M. E. Reid, et al. (2002). "Baseline characteristics and the effect 
of selenium supplementation on cancer incidence in a randomized clinical trial: A 
summary report of the Nutritional Prevention of Cancer Trial." Cancer 
Epidemiology Biomarkers & Prevention 11(7): 630-639. 
Finley, J. W. (2006). "Bioavailability of selenium from foods." Nutrition Reviews 64(3): 
146-151. 
Finley, J. W. and C. D. Davis (2001). "Selenium (Se) from high-selenium broccoli is 
utilized differently than selenite, selenate and selenomethionine, but is more 
effective in inhibiting colon carcinogenesis." Biofactors 14(1-4): 191-196. 
Fischer, J. L., E. M. Mihelc, et al. (2007). "Chemotherapeutic selectivity conferred by 
selenium: a role for p53-dependent DNA repair." Molecular Cancer Therapeutics 
6(1): 355-361. 
Ganther, H. E. (1999). "Selenium metabolism, selenoproteins and mechanisms of cancer 
prevention: complexities with thioredoxin reductase." Carcinogenesis 20(9): 
1657-1666. 
Gladyshev, V. N., T. C. Stadtman, et al. (1999). "Levels of major selenoproteins in T 
cells decrease during HIV infection and low molecular mass selenium compounds 
increase." Proceedings of the National Academy of Sciences of the United States 
of America 96(3): 835-839. 
Gropper, S., Smith, J., Groff, J. (2009). Advanced Nutrition and Human Metabolism, 
Wadsworth Cengage Learning. 
Hoffmann, F. W., A. C. Hashimoto, et al. "Dietary Selenium Modulates Activation and 
Differentiation of CD4(+) T Cells in Mice through a Mechanism Involving 
Cellular Free Thiols." Journal of Nutrition 140(6): 1155-1161. 
Hurst, R., C. N. Armah, et al. (2010). "Establishing optimal selenium status: results of a 
randomized, double-blind, placebo-controlled trial." American Journal of Clinical 
Nutrition 91(4): 923-931. 
89 
 
Kennedy, J. D., C. W. Pierce, et al. (1992). "EXTRATHYMIC T-CELL MATURATION 
- PHENOTYPIC ANALYSIS OF T-CELL SUBSETS IN NUDE-MICE AS A
FUNCTION OF AGE." Journal of Immunology 148(6): 1620-1629. 
Kiremidjian-Schumacher, L. and M. Roy (2001). "Effect of selenium on the 
immunocompetence of patients with head and neck cancer and on adoptive 
immunotherapy of early and established lesions." Biofactors 14(1-4): 161-168. 
Kryukov, G. V., S. Castellano, et al. (2003). "Characterization of mammalian 
selenoproteomes." Science 300(5624): 1439-1443. 
Lee, S. O., J. Y. Chun, et al. (2006). "Monomethylated selenium inhibits growth of 
LNCaP human prostate cancer xenograft accompanied by a decrease in the 
expression of androgen receptor and prostate-specific antigen (PSA)." Prostate 
66(10): 1070-1075. 
Levander, O. A. (1986). Selenium. Trace Elements in Human and Animal Nutrition. W. 
Mertz, Academic Press, Imc. 2: 209-279. 
Levander, O. A. (1987). "A GLOBAL VIEW OF HUMAN SELENIUM NUTRITION." 
Annual Review of Nutrition 7: 227-250. 
Li, G. X., H. J. Lee, et al. (2008). "Superior in vivo inhibitory efficacy of methylseleninic 
acid against human prostate cancer over selenomethionine or selenite." 
Carcinogenesis 29(5): 1005-1012. 
Lin, Y., L. M. Boylan, et al. (1991). "EFFECT OF DIETARY SELENIUM AND 
MAGNESIUM ON HUMAN MAMMARY-TUMOR GROWTH IN ATHYMIC 
NUDE-MICE." Nutrition and Cancer-an International Journal 16(3-4): 239-248. 
Lindshield, B. L., N. A. Ford, et al. (2010). "Selenium, but Not Lycopene or Vitamin E, 
Decreases Growth of Transplantable Dunning R3327-H Rat Prostate Tumors." 
Plos One 5(4). 
Lippman, S. M., P. J. Goodman, et al. (2005). "Designing the selenium and vitamin E 
cancer prevention trial (SELECT)." Journal of the National Cancer Institute 97(2): 
94-102. 
Lippman, S. M., E. A. Klein, et al. (2009). "Effect of Selenium and Vitamin E on Risk of 
Prostate Cancer and Other Cancers The Selenium and Vitamin E Cancer 
Prevention Trial ( SELECT)." Jama-Journal of the American Medical Associati n 
301(1): 39-51. 
Manning, D. D., N. D. Reed, et al. (1973). "MAINTENANCE OF SKIN XENOGRAFTS 
OF WIDELY DIVERGENT PHYLOGENETIC ORIGIN ON CONGENITALLY 
ATHYMIC (NUDE) MICE." Journal of Experimental Medicine 138(2): 488-494. 
90 
 
Meeker, H. C., M. L. Eskew, et al. (1985). "ANTIOXIDANT EFFECTS ON CELL-
MEDIATED-IMMUNITY." Journal of Leukocyte Biology 38(4): 451-458. 
Micke, O., L. Schomburg, et al. (2009). "Selenium in Oncology: From Chemistry to 
Clinics." Molecules 14(10): 3975-3988. 
Mostert, V. (2000). "Selenoprotein P: Properties, functions, and regulation." Archives of 
Biochemistry and Biophysics 376(2): 433-438. 
Muecke, R., J. Buentzel, et al. (2009). "Postoperative serum and whole blood selenium 
levels in patients with squamous cell and adenocarcinomas of the uterus after 
curative surgical treatment." Trace Elements and Electrolytes 26(2): 78-82. 
Papp, L. V., J. Lu, et al. (2007). "From selenium to selenoproteins: Synthesis, identity, 
and their role in human health." Antioxidants & Redox Signaling 9(7): 775-806. 
Rayman, M. P. (2004). "The use of high-selenium yeast to raise selenium status: how 
does it measure up?" British Journal of Nutrition 92(4): 557-573. 
Rayman, M. P. (2008). "Food-chain selenium and human health: emphasis on intake." 
British Journal of Nutrition 100(2): 254-268. 
Reed, N. D. and D. D. Manning (1973). "LONG-TERM MAINTENANCE OF 
NORMAL HUMAN SKIN ON CONGENITALLY ATHYMIC (NUDE) MICE." 
Proceedings of the Society for Experimental Biology and Medicine 143(2): 350-
353. 
Rotruck, J. T., A. L. Pope, et al. (1973). "SELENIUM - BIOCHEMICAL ROLE AS A 
COMPONENT OF GLUTATHIONE PEROXIDASE." Science 179(4073): 588-
590. 
Saliba, W., R. El Fakih, et al. "Heart failure secondary to selenium deficiency, reversible 
after supplementation." International Journal of Cardiology 141(2): E26-E27. 
Schwarz, K. and C. M. Foltz (1957). "SELENIUM AS AN INTEGRAL PART OF 
FACTOR-3 AGAINST DIETARY NECROTIC LIVER DEGENERATION." 
Journal of the American Chemical Society 79(12): 3292-3293. 
Schweizer, U., M. Michaelis, et al. (2004). "Efficient selenium transfer frommother to 
offspring in selenoprotein-P-deficient mice enables dose-dependent rescue of 
phenotypes associated with selenium deficiency." Biochemical Journal 378: 21-
26. 
Shamberg.Rj and D. V. Frost (1969). "POSSIBLE PROTECTIVE EFFECT OF 
SELENIUM AGAINST HUMAN CANCER." Canadian Medical Association 
Journal 100(14): 682-&. 
91 
 
Shrimali, R. K., R. D. Irons, et al. (2008). "Selenoproteins mediate T cell immunity 
through an antioxidant mechanism." Journal of Biological Chemistry 283(29): 
20181-20185. 
Spallholz, J. E., L. M. Boylan, et al. (1990). "ADVANCES IN UNDERSTANDING 
SELENIUM ROLE IN THE IMMUNE-SYSTEM." Annals of the New York 
Academy of Sciences 587: 123-139. 
Sunde, R. A., G. E. Gutzke, et al. (1981). "EFFECT OF DIETARY METHIONINE ON 
THE BIOPOTENCY OF SELENITE AND SELENOMETHIONINE IN THE 
RAT." Journal of Nutrition 111(1): 76-86. 
Surh, Y. J. (2003). "Cancer chemoprevention with dietary phytochemicals." Nature 
Reviews Cancer 3(10): 768-780. 
Thomson, C. D., A. Chisholm, et al. (2008). "Brazil nuts: an effective way to improve 
selenium status." American Journal of Clinical Nutrition 87(2): 379-384. 
Vogt, T. M., R. G. Ziegler, et al. (2003). "Serum selenium and risk of prostate cancer in 
US blacks and whites." International Journal of Cancer 103(5): 664-670. 
Wang, C. M., Y. Y. Wu, et al. (2009). "Induced Susceptibility of Host Is Associated with 
an Impaired Antioxidant System Following Infection with Cryptosporidium 
parvum in Se-Deficient Mice." Plos One 4(2). 
Watrach, A. M., J. A. Milner, et al. (1984). "INHIBITION OF HUMAN-BREAST 
CANCER-CELLS BY SELENIUM." Cancer Letters 25(1): 41-47. 
Weeks, M. E. (1932). "The discovery of the elements.III. Some eighteenth-century 
metals." Journal of chemical education: 22. 
Whanger, P., V. Xia, et al. (1993). "METABOLISM OF DIFFERENT FORMS OF 
SELENIUM IN HUMANS." Journal of Trace Elements and Electrolytes in 
Health and Disease 7(2): 121-121. 
Wu, M., M. M. Kang, et al. (2010). "Selenium Compounds Activate Early Barriers of 
Tumorigenesis." Journal of Biological Chemistry 285(16): 12055-12062. 
Xia, Y. M., K. E. Hill, et al. (2005). "Effectiveness of selenium supplements in a low-
selenium area of China." American Journal of Clinical Nutrition 81(4): 829-834. 
Yang, G. and R. Zhou (1994). "FURTHER OBSERVATIONS ON THE HUMAN 
MAXIMUM SAFE DIETARY SELENIUM INTAKE IN A SELENIFEROUS 
AREA OF CHINA." Journal of Trace Elements and Electrolytes in Health and 
Disease 8(3-4): 159-165. 
92 
 
Yang, Y., F. Huang, et al. (2009). "The Anticancer Effects of Sodium Selenite and 
Selenomethionine on Human Colorectal Carcinoma Cell Lines in Nude Mice." 
Oncology Research 18(1): 1-8. 
Yoshizawa, K., W. C. Willett, et al. (1998). "Study of prediagnostic selenium level in 
toenails and the risk of advanced prostate cancer." Journal of the National Cancer 
Institute 90(16): 1219-1224. 
Zeng, H. W. (2009). "Selenium as an Essential Micronutrient: Roles in Cell Cycle and 
Apoptosis." Molecules 14(3): 1263-1278. 
 
 
